Therefore, it remains incredibly important to decide when immunotherapy, using PD-1/PD-L1 immune checkpoint blockade as a 1st line therapy, is the right strategy for NSCLC patients (43). The gene discussed is CD274; the disease is non-small cell lung carcinoma.